Li Xueyan, Zhu Yanying, Xie Haiyan, Chen Yuexin, Liu Yukun, Xu Xiaochen, Wang Jing
The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.
Wuhu City Eye Hospital, Wuhu, China.
Front Med (Lausanne). 2025 Jun 24;12:1585396. doi: 10.3389/fmed.2025.1585396. eCollection 2025.
To investigate the changes in the ocular surface and meibomian glands following the administration of 0.01 and 0.02% atropine.
The Second Affiliated Hospital of Anhui Medical University, Anhui, China.
In this randomized controlled study, the 0.01% group (18 patients, 36 eyes) and the 0.02% group (15 patients, 30 eyes) underwent assessments using the Ocular Surface Disease Index (OSDI), Visual Analogue scale (VAS), tear meniscus height (TMH), first noninvasive tear film breakup time (fNIBUT), and average noninvasive tear film breakup time (avNIBUT) at baseline (before administration) and at 1, 3, 6, and 12 months post-treatment. The meibomian glands of both the upper (U) and lower (L) eyelids were evaluated using Meibomian Gland Bio-image Analyzer, measuring parameters such as average gland diameter (avGD), average gland length (avGL), average gland area (avGA), deformation coefficient (DC), and gland visibility score (VS).
There were no statistically significant differences in any of the parameters within the 0.01% group (all > 0.05). In the within-group comparisons of the 0.02% group, OSDI was higher at 3 month ( = 0.006) and was lower at 12 months ( = 0.038). VAS was higher at 3 months and 6 months (all < 0.05). TMH was lower at 12 months (all < 0.05). U-VS was lower at 3 months ( = 0.006) and higher at 6 and 12 months (all p < 0.05). L-avGL was higher at 1 month ( = 0.001) and lower at 6 months ( = 0.013). L-VS was higher at 6 and 12 months (all < 0.05). In the 0.02% group, at 3 months, the change in U-VS and L-VS were positively correlated with the change in the VAS (r = 0.542, = 0.037; r = 0.614, = 0.015). At 6 months, the change in L-VS was positively correlated with the change in OSDI (r = 0.610, = 0.016). At 12 months, the change in U-VS was positively correlated with the change in TMH (r = 0.521, = 0.003).
0.01% atropine had no significant impact. 0.02% atropine eye drops affected the lipid secretion of meibomian glands, tear meniscus height and subjective discomfort.
研究0.01%和0.02%阿托品给药后眼表及睑板腺的变化。
中国安徽安徽医科大学第二附属医院。
在这项随机对照研究中，0.01%组（18例患者，36只眼）和0.02%组（15例患者，30只眼）在基线（给药前）以及治疗后1、3、6和12个月使用眼表疾病指数（OSDI）、视觉模拟量表（VAS）、泪河高度（TMH）、首次无创泪膜破裂时间（fNIBUT）和平均无创泪膜破裂时间（avNIBUT）进行评估。使用睑板腺生物图像分析仪评估上睑（U）和下睑（L）的睑板腺，测量平均腺体直径（avGD）、平均腺体长度（avGL）、平均腺体面积（avGA）、变形系数（DC）和腺体可见度评分（VS）等参数。
0.01%组内任何参数均无统计学显著差异（均P>0.05）。在0.02%组的组内比较中，OSDI在3个月时较高（P=0.006），在12个月时较低（P=0.038）。VAS在3个月和6个月时较高（均P<0.05）。TMH在12个月时较低（均P<0.05）。U-VS在3个月时较低（P=0.006），在6个月和12个月时较高（均P<0.05）。L-avGL在1个月时较高（P=0.001），在6个月时较低（P=0.013）。L-VS在6个月和12个月时较高（均P<0.05）。在0.02%组中，3个月时，U-VS和L-VS的变化与VAS的变化呈正相关（r=0.542，P=0.037；r=0.614，P=0.015）。6个月时，L-VS的变化与OSDI的变化呈正相关（r=0.610，P=0.016）。12个月时，U-VS的变化与TMH的变化呈正相关（r=0.521，P=0.003）。
0.01%阿托品无显著影响。0.02%阿托品滴眼液影响睑板腺脂质分泌、泪河高度和主观不适。
